Neuropathic Pain News and Research

RSS

Neuropathic pain is a type of pain that is caused by damage to the nervous system following an injury or illness and affects approximately 1% of the population.

Spinifex announces results of Phase 2 clinical trial of EMA401 in postherpetic neuralgia

Spinifex Pharmaceuticals, an Australian pain drug development company, today announces that The Lancet has published the results of its Phase 2 clinical trial of its lead candidate, EMA401, in postherpetic neuralgia (PHN).

5 Feb 2014

New drug treatment effective against chronic pain caused by nerve damage post shingles

A new drug treatment has been found to be effective against chronic pain caused by nerve damage, also known as neuropathic pain, in patients who have had shingles.

5 Feb 2014

Scientists identify channel that acts as 'brake', limiting spontaneous pain

Scientists have identified a channel present in many pain detecting sensory neurons that acts as a 'brake', limiting spontaneous pain. It is hoped that the new research, published today [22 January] in the Journal of Neuroscience, will ultimately contribute to new pain relief treatments.

22 Jan 2014

University of Huddersfield scientist awarded prestigious Clulow Award by British Pain Society

IN the UK alone, an estimated 7.8 million people have their lives blighted by chronic pain, and 44 per cent are failing to receive an accurate diagnosis and appropriate treatment. Now, a University of Huddersfield scientist, backed by funding from the British Pain Society and crucial support from the National Institute of Health Research, is embarking on research which aims to help doctors diagnose and treat one of the least understood but most widespread sources of chronic suffering.

18 Jan 2014

$Japanese MHLW approves ADCETRIS for relapsed or refractory CD30-positive HL and ALCL$

Japanese MHLW approves ADCETRIS for relapsed or refractory CD30-positive HL and ALCL

Seattle Genetics, Inc. today announced that its collaborator, Takeda Pharmaceutical Company Limited, has received approval of ADCETRIS (brentuximab vedotin) from the Japanese Ministry of Health, Labour and Welfare for the treatment of patients with CD30-positive relapsed or refractory Hodgkin lymphoma and anaplastic large cell lymphoma.

18 Jan 2014

ARIAD Pharmaceuticals' Iclusig now commercially available to patients in the U.S.

ARIAD Pharmaceuticals, Inc. today announced the commercial availability of Iclusig (ponatinib) for adult patients with refractory chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia in the United States. ARIAD has begun shipping Iclusig to Biologics, Inc., its exclusive specialty pharmacy, which is now filling prescriptions from physicians and distributing the cancer medicine to patients.

18 Jan 2014

Chinese herbal medicine effective at alleviating acute inflammatory and nerve pain

A compound derived from a traditional Chinese herbal medicine has been found effective at alleviating pain, pointing the way to a new nonaddictive analgesic for acute inflammatory and nerve pain, according to UC Irvine pharmacology researchers.

3 Jan 2014

Researchers use ATX-Red AR-2 as new imaging agent to illuminate tumors

Researchers from Echelon Biosciences, Inc. and collaborators from the University of Utah report the use of ATX-Red AR-2 as a new imaging agent that effectively illuminates tumors.

17 Dec 2013

Medivir initiates phase IIa trial to evaluate efficacy of simeprevir combination therapy in HCV-infected patients

Medivir AB (STO:MVIR-B) (OMX: MVIR), announces the initiation of a phase IIa trial in chronic genotype 1 hepatitis C infected patients to evaluate the efficacy, safety and tolerability of a 12-week combination therapy of simeprevir, TMC647055 and JNJ56914845, a NS5A replication complex inhibitor.

12 Dec 2013

Avanir Pharmaceuticals' AVP-923 phase II trial fails to meet primary efficacy endpoint

Avanir Pharmaceuticals, Inc. today announced that PRIME, its phase II clinical trial of the investigational drug AVP-923 (dextromethorphan / quinidine) for the treatment of central neuropathic pain in patients with multiple sclerosis did not meet the primary efficacy endpoint.

10 Dec 2013

Vitamin D2 supplementation is promising treatment for pain, depression in type 2 diabetes

Vitamin D decreases pain in women with type 2 diabetes and depression, according to a study conducted at Loyola University Chicago. These findings were presented at an Oct. 24, 2013 research conference at Loyola's Health Sciences Campus.

2 Dec 2013

Study suggests role for brain imaging in potential treatment of chronic pain

A study in the December issue of Anesthesiology suggests a role for brain imaging in the assessment and potential treatment of chronic pain.

20 Nov 2013

Zalicus announces top-line results from Z160 Phase 2 clinical studies in chronic pain indications

Zalicus Inc., a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain, today announced top-line results from two Phase 2 clinical studies of Z160 in chronic pain indications.

11 Nov 2013

Molecular mechanisms underlying effects of acupuncture on neuropathic pain

Peripheral or central nerve injury often leads to neuropathic pain, a chronic condition that can manifest behaviorally as spontaneous pain, hyperalgesia and allodynia, and which also results in neurological dysfunction.

6 Nov 2013

Generic drug gabapentin appears to be safe, effective in treating alcohol dependence

The generic drug gabapentin, which is already widely prescribed for epilepsy and some kinds of pain, appears to be safe and effective in the treatment of alcohol dependence. The finding comes from a 150-patient randomized, placebo-controlled, double blind clinical trial conducted by scientists at The Scripps Research Institute.

4 Nov 2013

High-definition transcranial direct current stimulation helps treat pain in fibromyalgia patients

Imagine significantly reducing a persistent migraine or fibromyalgia by a visit to a doctor who delivers low doses of electricity to the brain.

30 Oct 2013

Pfizer announces top-line results from phase 3b studies with Lyrica Capsules

Pfizer Inc. (NYSE:PFE) announced top-line results from two phase 3b, placebo-controlled studies with Lyrica® (pregabalin) Capsules CV in patients with fibromyalgia (FM) and painful diabetic peripheral neuropathy (DPN), respectively.

19 Oct 2013

Medivir announces data from phase III studies of simeprevir in patients co-infected with HCV genotype-1 and HIV-1

Medivir AB (OMX:MVIR-B) today announced preliminary data from two phase III studies conducted by Janssen R&D Ireland evaluating simeprevir in genotype 4 chronic hepatitis C in adult patients with compensated liver disease, and in genotype 1 hepatitis C and HIV-1 co-infected adult patients.

19 Oct 2013

Acorda Therapeutics initiates second clinical trial of Glial Growth Factor 2 in heart failure patients

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that the first patient has been enrolled in the second clinical trial of Glial Growth Factor 2 (GGF2). This Phase 1b single-infusion trial in people with heart failure will assess tolerability of three dose levels of GGF2, and also includes several explorative measures of efficacy.

9 Oct 2013

Lpath receives NIH SBIR grant to investigate effect of Lpathomab compound on diabetic neuropathy

Lpath, Inc., the industry leader in lipidomics-based therapeutics, announced receipt of a Notice of Grant Award from the National Institutes of Health (NIH). This $145,000 Phase 1 SBIR grant will support the study of Lpath's therapeutic monoclonal antibody, Lpathomab™, in animal models of diabetic neuropathic pain and diabetic neuropathy.

23 Sep 2013

Neuropathic Pain News and Research

Further Reading

Spinifex announces results of Phase 2 clinical trial of EMA401 in postherpetic neuralgia

New drug treatment effective against chronic pain caused by nerve damage post shingles

Scientists identify channel that acts as 'brake', limiting spontaneous pain

University of Huddersfield scientist awarded prestigious Clulow Award by British Pain Society

Japanese MHLW approves ADCETRIS for relapsed or refractory CD30-positive HL and ALCL

ARIAD Pharmaceuticals' Iclusig now commercially available to patients in the U.S.

Chinese herbal medicine effective at alleviating acute inflammatory and nerve pain

Researchers use ATX-Red AR-2 as new imaging agent to illuminate tumors

Medivir initiates phase IIa trial to evaluate efficacy of simeprevir combination therapy in HCV-infected patients

Avanir Pharmaceuticals' AVP-923 phase II trial fails to meet primary efficacy endpoint

Vitamin D2 supplementation is promising treatment for pain, depression in type 2 diabetes

Study suggests role for brain imaging in potential treatment of chronic pain

Zalicus announces top-line results from Z160 Phase 2 clinical studies in chronic pain indications

Molecular mechanisms underlying effects of acupuncture on neuropathic pain

Generic drug gabapentin appears to be safe, effective in treating alcohol dependence

High-definition transcranial direct current stimulation helps treat pain in fibromyalgia patients

Pfizer announces top-line results from phase 3b studies with Lyrica Capsules

Medivir announces data from phase III studies of simeprevir in patients co-infected with HCV genotype-1 and HIV-1

Acorda Therapeutics initiates second clinical trial of Glial Growth Factor 2 in heart failure patients

Lpath receives NIH SBIR grant to investigate effect of Lpathomab compound on diabetic neuropathy

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News